natgillin/translations-raw huggingface dataset:
This should be discussed
O tem se pogovorite
Then continue taking your capsules as normal.
Potem nadaljujte z jemanjem kapsul kot po navadi.
Interaction (postulated mechanism of action, if known)
Medsebojno delovanje (predvideni mehanizem delovanja, če je znan)
Component of a multipack, can't be sold separately
Del multi-pakiranja, se ne prodaja posamezno.
Therefore, you and your partner must take special precautions in sexual activity if there is any chance for pregnancy to occur:
Vi in vaš partner morata biti zato posebej pazljiva pri spolnih odnosih, če obstaja kakršna koli možnost za zanositev:
84 hard capsules.
84 trdih kapsul.
tongue or throat - these are signs of an allergic reaction.
ustnic, jezika ali žrela - to so znaki alergijske reakcije.
Take the capsules in the morning, afternoon and evening with a meal or light snack.
Kapsule vzemite zjutraj, popoldan in zvečer ob obroku ali z lahkim prigrizkom.
• The Summary of Product Characteristics (in full)
• Povzetek glavnih značilnosti zdravila (v celoti),
• The active substance is boceprevir.
• Učinkovina je boceprevir.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o
Red printing ink containing:
Rdeče črnilo za tisk, ki vsebuje:
Daily doses of 3,600 mg have been taken by healthy volunteers for 5 days without untoward symptomatic effects.
Zdravi prostovoljci so 5 dni jemali dnevne odmerke 3.600 mg brez neugodnih simptomatskih učinkov.
Clinical Study
Klinična študija
These recommendations are based on either drug interaction studies (indicated with *) or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy.
Ta priporočila temeljijo ali na študijah medsebojnega delovanja (označeno z *) ali predvidenega medsebojnega delovanja zaradi pričakovanega obsega interakcij in možnosti za resne neželene učinke ali zmanjšanja učinkovitosti.
Prompt evaluation and treatment of infections is recommended.
Priporočamo takojšnjo oceno in zdravljenje okužb.
Your doctor may need to increase the frequency of your blood tests to check how well your blood can
Zdravnik bo morda moral povečati pogostnost krvnih preiskav, da bo lahko spremljal, kako dobro se lahko vaša kri strjuje.
• so your doctor knows if the treatment is working for you
• da bo zdravnik vedel, ali zdravljenje pri vas deluje,
The use without food could seriously compromise your chance of success of treatment.
Uporaba brez hrane lahko bistveno zmanjša možnosti za uspeh zdravljenja.
SPRINT-2 (previously untreated subjects)
SPRINT-2 (predhodno nezdravljeni preiskovanci)
< 1-log10 decline
< 1-log10 zmanjšanje
• some neuroleptics
• nekatere nevroleptike
• Hypersensitivity to the active substance or any of the excipients listed in section 6.1.
• Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
Stop taking Victrelis and see a doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment:
Prenehajte jemati zdravilo Victrelis in takoj obiščite zdravnika, če opazite katerega od naslednjih resnih neželenih učinkov - morda boste potrebovali nujno zdravljenje:
*Please see section 5.1 clinical trial descriptions for each treatment arm.
*Prosimo, glejte opise kliničnih preskušanj v poglavju 5.1 za vsako skupino zdravljenja.
• have another liver problem in addition to hepatitis C infection • have HIV (human immunodeficiency virus) or have ever had any other problems with your
• če imate druge težave z jetri poleg okužbe s hepatitisom C, • če imate HIV (virus humane imunske pomanjkljivosti) ali ste kdaj imeli kakšne druge težave z
Other clinical experience has not identified differences in responses between the older and younger patients (see section 5.2).
Druge klinične izkušnje niso pokazale razlik v odzivu med starejšimi in mlajšimi bolniki (glejte poglavje 5.2).
Detailed information on this medicine is available on the European Medicines Agency web site:
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila:
Exposure to boceprevir in nursing human infants is estimated to be less than 1% of the dose.
Ocenjujejo, da je izpostavljenost boceprevirju pri človeških dojenčkih manj kot 1 % odmerka.
• Do not take a double dose to make up for a forgotten dose.
• Ne vzemite dvojnega odmerka, da bi nadoknadili izpuščeni odmerek.
(Refer to the stopping rule in Table 1 for all patients.)
(Za vse bolnike glejte pravilo prenehanja zdravljenja v preglednici 1.)
Loss of replicon RNA appears to be first-order with respect to time of treatment.
Upad replikacijske enote RNA je, kot kaže, prvega reda glede na čas zdravljenja.
This includes medicines obtained without a prescription and herbal medicines.
To velja tudi za zdravila, ki ste jih dobili brez recepta in za zdravila
Accumulation is minimal and pharmacokinetic steady state is achieved after approximately 1 day of three times daily dosing.
Kopičenje je minimalno, farmakokinetično stanje dinamičnega ravnovesja je doseženo po približno 1 dnevu uporabe trikrat na dan.
• have or anyone in your family has an irregular heartbeat, especially a condition called “QT
• če imate ali ima kdo iz vaše družine nepravilen srčni utrip, še posebej stanje, imenovano
The safety and efficacy of Victrelis in children aged below 18 years have not yet been established.
Varnost in učinkovitost zdravila Victrelis pri otrocih do 18. leta starosti še nista dokazani.
Neutropenia affects the body's ability to fight off infections
Nevtropenija prizadane zmožnost telesa za borbo proti okužbam.
• The duration of the administration of these medicines will depend on your response and
• Čas jemanja teh zdravil bo odvisen od vašega odziva in načrta zdravljenja.
• warfarin and other similar medicines called vitamin K antagonists used to thin the blood.
• varfarin in druga podobna zdravila, imenovana antagonisti vitamina K, ki se uporabljajo za redčenje krvi.
Titanium dioxide (E171) Yellow iron oxide (E172) Red iron oxide (E172)
želatina titanov dioksid (E171) rumeni železov oksid (E172) rdeči železov oksid (E172)
Inner carton without Blue Box
Notranja škatla brez modrega okvirčka
• have ever had a blood problem such as neutropenia (lack of a certain type of white blood cells).
• če ste kdaj imeli težave s krvjo, kot je nevtropenija (pomanjkanje določene vrste belih krvnih celic).
Data obtained in juvenile rats suggest that the pharmacokinetic profile of boceprevir may be different than in adult rats, possibly due to immaturity of some metabolic pathways.
Podatki, pridobljeni pri podganjih mladičih, kažejo, da je farmakokinetični profil boceprevirja lahko drugačen kot pri odraslih podganah, možno zaradi nezrelosti nekaterih metabolnih poti.
The last available value in the period at and after FW 24.
Zadnja razpoložljiva vrednost v in po 24.
It should be noted that retrospective analyses bridging the data between the two pivotal studies have led to a recommended posology that differs from the regimen studied in some patient subgroups.
Upoštevati je treba, da so retrospektivne analize, ki so povezale podatke iz dveh ključnih študij, pripeljale do priporočenega odmerjanja, ki se pri nekaterih podskupinah bolnikov razlikuje od preučevanega režima.
• to help your doctor decide how long you will be treated with Victrelis.
• za pomoč zdravniku pri presoji, kako dolgo se morate zdraviti z zdravilom Victrelis,
Clinical studies of boceprevir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Klinične študije boceprevirja niso vključevale zadostnega števila preiskovancev, starih 65 let in več, da bi bilo mogoče ugotoviti, ali se starejši preiskovanci odzivajo drugače kot mlajši.
The data indicate that boceprevir is eliminated primarily by the liver.
Podatki kažejo, da se boceprevir izloča primarno preko jeter.
Effects of food on oral absorption
Vpliv hrane na absorpcijo po peroralni uporabi
o The duration of the tritherapy after the first 4 weeks of bitherapy should not be less than 32 weeks.
o Trajanje trojnega zdravljenja po prvih štirih tednih dvojnega zdravljenja ne sme biti krajše od 32 tednov.
See section 4.
Odziv v 4.
Caution is warranted and clinical monitoring of patients is recommended.
Potrebna je previdnost in priporočljiv je kliničen nadzor bolnikov.
The results of this retrospective subgroup analysis should be viewed with caution because of the small sample size and potential differences of the sub-study population relative to the overall trial
Rezultate retrospektivne analize v tej podskupini je treba previdno tolmačiti zaradi majhne velikosti vzorca in morebitnih razlik te populacije glede na celotno
Patients should be monitored for signs of opiate toxicity associated with buprenorphine.
Bolnike je treba spremljati glede znakov opiatne toksičnosti, povezane z buprenorfinom.
Treatment of overdose with Victrelis should consist of general supportive measures, including monitoring of vital signs, and observation of the patient's clinical status.
Zdravljenje prevelikega odmerjanja zdravila Victrelis mora obsegati splošne podporne ukrepe, vključno z nadziranjem vitalnih znakov in opazovanjem bolnikovega kliničnega stanja.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy with Victrelis taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prenehanje/prekinitev zdravljenja z zdravilom Victrelis, upoštevaje korist dojenja za otroka in korist zdravljenja za žensko.
The percent change and arrows (↑ = increase, ↓ = decrease, ↔ = no change) are used to show the magnitude and direction of change in mean ratio estimate for each pharmacokinetic parameter.
Odstotek spremembe in puščice (↑ = povečanje, ↓ = zmanjšanje, ↔ =ni spremembe) prikazujejo obseg in smer spremembe povprečne ocene razmerja za vsak farmakokinetični parameter.
The hepatocellular tumours are considered due to enzyme induction and therefore not relevant for humans.
Tumorji jetrnih celic veljajo za posledico encimske indukcije in zato niso pomembni za človeka.
Laboratory testing
Laboratorijske preiskave
3 and/or serum albumin < 35 g/L and/or signs of coagulopathy (International Normalized Ratio (INR) > 1.7) at baseline.
3 in/ali serumski albumin < 35 g/l in/ali znake koagulopatije (internacionalno normalizirano razmerje (INR) > 1,7).
For most of these subjects (n=54), the lowest dose of ribavirin received for at least 14 days was ≥ 600mg/day.
Za večino teh preiskovancev (n=54) je bil najnižji odmerek ribavirina, ki so ga prejemali vsaj 14 dni, ≥ 600 mg/dan.
Within each system organ class, adverse reactions are listed under headings of frequency using the categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); not known (cannot be estimated from the available data).
Znotraj posameznih organskih sistemov so neželeni učinki razvrščeni po pogostnosti upoštevaje naslednje kategorije: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
If you have any questions about what to do, talk to your doctor.
Če imate kakšno vprašanje o tem, kako ravnati, se posvetujte z zdravnikom.
• have a current or previous infection with the hepatitis B virus, since your doctor may want to
• če imate ali ste imeli okužbo z virusom hepatitisa B, ker vas bo zdravnik morda želel bolj skrbno
What Victrelis is and what it is used for What you need to know before you take Victrelis
Kaj je zdravilo Victrelis in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Victrelis
Sustained Virologic Response (SVR) to treatment was defined as undetectable
Trajen virološki odziv (SVR) na zdravljenje je bil opredeljen kot nezaznavna
No clinical paediatric exposure data is available (see section 4.2).
Kliničnih pediatričnih podatkov o izpostavljenosti ni na voljo (glejte poglavje 4.2).
The clinical outcome of this observed reduction of Victrelis trough concentrations has not been directly assessed.
Klinični izid tega opaženega zmanjšanja najmanjše koncentracije zdravila Victrelis ni bil neposredno ocenjen.
At Treatment Week 8
8. teden zdravljenja
Patients should be informed that fatigue, dizziness, syncope, blood pressure fluctuations and blurred vision have been reported (see section 4.8).
Bolnikom je treba povedati, da so poročali o utrujenosti, omotici, sinkopi, nihanju krvnega tlaka in zamegljenem vidu (glejte poglavje 4.8).
The bioavailability of boceprevir is regardless of meal type (e.g., high-fat vs. low-fat) or whether taken 5 minutes prior to eating, during a meal, or immediately following completion of the meal.
Na biološko uporabnost boceprevirja ne vpliva vrsta obroka (npr. zelo masten v primerjavi z malo mastnim) in tudi ne, ali je zaužit 5 minut pred jedjo, med jedjo ali takoj po koncu obroka.
Boceprevir is not eliminated by dialysis.
Boceprevir se ne odstrani z dializo.
When boceprevir is administered with ritonavir alone, boceprevir concentrations are decreased.
Če se boceprevir uporablja samo z ritonavirjem, se koncentracija boceprevirja zniža.
The recommended dose of Victrelis is 4 capsules three times a day (a total of 12 capsules a day).
Priporočeni odmerek zdravila Victrelis je 4 kapsule trikrat na dan (skupaj 12 kapsul na dan).
Outer carton with Blue Box
Zunanja škatla z modrim okvirčkom
What Victrelis is and what it is used for
Kaj je zdravilo Victrelis in za kaj ga uporabljamo
The D168V single substitution did not reduce sensitivity to boceprevir.
Enojna zamenjava D168V ni zmanjšala občutljivosti za boceprevir.
Steady state AUC, Cmax and Cmin increased in a less-than dose-proportional manner and individual exposures overlapped substantially at 800 mg and 1,200 mg, suggesting diminished absorption at higher doses.
AUC, Cmax in Cmin v stanju dinamičnega ravnovesja so se povečevale manj kot sorazmerno odmerku, individualne izpostavljenosti pri 800 mg in 1.200 mg pa so se bistveno prekrivale, kar kaže zmanjšano absorpcijo pri večjih odmerkih.
At steady-state, the exposure ratio for the two diastereomers is approximately 2:1, with the predominant diastereomer being pharmacologically active.
V stanju dinamičnega ravnovesja je delež izpostavljenosti obema diastereoizomerama približno 2:1, pri čemer je prevladujoča diastereomera farmakološko
The most common HIV PI taken was atazanavir followed by lopinavir and darunavir.
Najpogosteje uporabljen HIV PI je bil atazanavir, ki mu sledita lopinavir in darunavir.
IL28B rs12979860 Genotype
IL28B rs12979860 genotip
Prolonged exposure resulted in a 2-log decrease in RNA levels by Day 15.
Dolgotrajna izpostavljenost je povzročila 2-log zmanjšanje koncentracije RNA do 15. dne.
≥ 1-log10 decline
≥ 1-log10
• This medicine should be taken with a meal or light snack.
• Zdravilo morate vzeti ob obroku ali z lahkim prigrizkom.
Treatment at IC90 for 72 hours resulted in a 1-log10 drop in replicon RNA.
72-urno tretiranje z IC90 je povzročilo 1-log10 padec replikacijske enote RNA.
What you need to know before you take Victrelis
Kaj morate vedeti, preden boste vzeli zdravilo Victrelis
It is unknown what effect therapy with Victrelis will have on the activity of subsequently administered HCV protease inhibitors, including re-treatment with Victrelis.
Ni znano, kakšen bo učinek zdravljenja z zdravilom Victrelis na delovanje pozneje uporabljanih zaviralcev proteaz HCV, vključno s ponovnim zdravljenjem z zdravilom Victrelis.
Alpha-1 adrenoreceptor antagonists
Antagonisti adrenergičnih receptorjev alfa-1
The PEM should contain the following key elements:
Izobraževalno gradivo za zdravnike mora vsebovati naslednje ključne podatke:
For additional information on use of Victrelis in patients with advanced
Za dodatne informacije glede uporabe zdravila Victrelis pri bolnikih z napredovalo
No dose adjustment of escitalopram is anticipated, but doses may need to be adjusted based on clinical effect.
Prilagoditev odmerkov escitaloprama ni predvidena, vendar bo glede na klinični učinek, odmerke morda potrebno prilagoditi.
At Treatment Week 24
24. teden zdravljenja
ASSESSMENT* (HCV-RNA Results
DOLOČITEV* (HCV-RNA
• pimozide or lurasidone - used for mental health problems
• pimozid ali lurasidon - uporablja se za zdravljenje težav z duševnim zdravjem,
No carcinomas or adenomas were observed in rats.
Pri podganah niso ugotovili karcinomov ali adenomov.
The percentage of patients with Grades 3-4 neutropenia (neutrophil counts < 0.75 x 10
Odstotek bolnikov z nevtropenijo 3. do 4. stopnje (število nevtrofilcev < 0,75 x 10
• lumefantrine and halofantrine - anti-malaria medicines
• lumefantrin in halofantrin - zdravili proti malariji,
Maraviroc 150 mg twice daily when co-administered with boceprevir.
Maravirok 150 mg dvakrat na dan pri sočasni uporabi z boceprevirjem.
Boceprevir was absorbed following oral administration with a median Tmax of 2 hours.
Boceprevir se je po zaužitju absorbiral z medianim tmax 2 uri.
Also, tell your doctor or pharmacist if you are taking any of the following:
Prav tako morate zdravniku ali farmacevtu povedati, če jemljete katera od naslednjih zdravil:
In a study of patients with varying degrees of stable chronic liver impairment (mild, moderate and severe), no clinically significant differences in pharmacokinetic parameters were found, and no dose adjustment is recommended.
V študiji pri bolnikih z različnimi stopnjami stabilne kronične okvare jeter (blago, zmerno in hudo) niso ugotovili klinično pomembnih razlik v farmakokinetičnih parametrih, zato prilagoditev odmerka ni potrebna.
Point estimate of the difference (Victrelis-RGT minus VictrelisPR48) [95% CI]
Ocena razlike (Victrelis-RGT minus Victrelis-PR48) [95 % IZ]
• tyrosine kinase inhibitors - used as anti-cancer medicines
• zaviralce tirozin-kinaze - uporabljajo se kot zdravila proti raku.
The V55I and D168N single substitutions did not reduce sensitivity to boceprevir.
Enojni zamenjavi V55I in D168N nista zmanjšali občutljivosti za boceprevir.
Follow-up analysis of boceprevir-treated subjects who did not achieve SVR showed that the population of wild-type virus increased and the majority of boceprevir-resistant variants became undetectable over time after the end of boceprevir treatment.
Analiza spremljanja preiskovancev, zdravljenih z boceprevirjem, ki niso dosegli SVR, je pokazala, da se je populacija divjega tipa virusa povečala in da je večina na boceprevir odpornih variant virusa po koncu zdravljenja s časom postala nezaznavna.
Multipack: 336 (4 packs of 84) hard capsules
Multi-pakiranje: 336 (4 pakiranja po 84) trdih kapsul
The majority of the anaemia subjects received erythropoietin when haemoglobin levels were ≤ 10 g/dL (or 6.2 mmol/L).
Večina anemičnih preiskovancev je prejemala eritropoetin, če je bila koncentracija hemoglobina ≤ 10 g/dl (oz. 6,2 mmol/l).
Do not take Victrelis if you are taking any of the medicines above.
Ne vzemite zdravila Victrelis, če jemljete katero koli izmed zgoraj naštetih zdravil.
If you take more Victrelis than you should If you take more Victrelis than you should, talk to a doctor or go to the nearest hospital emergency
Če ste vzeli večji odmerek zdravila Victrelis, kot bi smeli Če ste vzeli večji odmerek zdravila Victrelis, kot bi smeli, se morate takoj posvetovati z zdravnikom ali iti v ambulanto za nujno medicinsko pomoč najbližje bolnišnice.
Use in patients with an organ transplant
Uporaba pri bolnikih s presajenim organom
The majority of subjects (87%; 85/98) were taking a ritonavir-boosted HIV protease inhibitor (PI) combined with HIV nucleoside reverse transcriptase inhibitors (NRTIs).
Večina preiskovancev (87 %; 85/98) je prejemala z ritonavirjem ojačani zaviralec HIV proteaze (PI), kombiniran z zaviralci HIV-nukleozidne reverzne transkriptaze (NRTIs).
The SVR rates for subjects who received at least one dose of any study medication (Intent-to-Treat population) are shown in Table 9.
Deleži SVR pri preiskovancih, ki so prejeli vsaj en odmerek katerega koli študijskega zdravila (populacija z namenom zdravljenja - ITT) so prikazani v Preglednici 9.
Pharmacokinetic results were similar between healthy subjects and HCV-infected subjects.
Farmakokinetični rezultati so bili pri zdravih preiskovancih in preiskovancih, okuženih s HCV, podobni.
Do not stop taking Victrelis unless your doctor tells you to.
Ne prenehajte jemati zdravila Victrelis, če vam tega ne naroči zdravnik.
There were 77 subjects who received ≥ 5 steps ribavirin dose reduction for the management of anaemia.
77 preiskovancev je za obvladovanje anemije prejelo za ≥ 5 korakov zmanjšan odmerek ribavirina.
• select statins - atorvastatin or pravastatin
• izbrane statine - atorvastatin ali pravastatin
Victrelis inhibits the direct replication of the virus and contributes in this way to lowering the amount
Zdravilo Victrelis zavira neposredno razmnoževanje virusa in na tak način pomaga zmanjšati količino
• have ever had a blood problem such as anaemia (when you lack enough healthy red blood cells, which transport oxygen around your body)
• če ste kdaj imeli težave s krvjo, kot je anemija (pomanjkanje zdravih rdečih krvnih celic, ki prenašajo kisik po telesu),
Boceprevir is primarily metabolized by aldoketo reductase (AKR).
Boceprevir se primarno presnavlja preko aldo/keto reduktaze (AKR).
ACTION
UKREPANJE
Close clinical monitoring is warranted.
Potreben je natančen klinični nadzor.
C-boceprevir, approximately 79% and 9% of the dose was excreted in faeces and urine, respectively, with approximately 8% and 3% of the dosed radiocarbon eliminated as boceprevir in faeces and urine.
C-boceprevirja se je približno 79 % odmerka izločilo v blatu in 9 % v urinu; približno 8 % uporabljenega radioaktivnega ogljika se je kot boceprevir izločilo v blatu in 3 % v urinu.
This regimen has only been tested in subjects who have failed previous therapy who were late responders (see section 5.1).
Ta režim je bil preizkušen le pri osebah s poznim odzivom, pri katerih predhodno zdravljenje ni bilo uspešno (glejte poglavje 5.1).
• quetiapine - used to treat schizophrenia, bipolar disorder and major depressive disorder
• kvetiapin - uporablja se za zdravljenje shizofrenije, bipolarne motnje in velike depresije,
Blood: low potassium levels in your blood; high calcium levels in the blood
Kri: nizka koncentracija kalija v krvi, visoka koncentracija kalcija v krvi
The absolute bioavailability of Victrelis has not been studied.
Absolutna biološka uporabnost zdravila Victrelis ni bila raziskana.
Ribavirin dose reduction is the preferred strategy for managing treatment-emergent anaemia (see section 5.1).
Zmanjšanje odmerka ribavirina je najprimernejši način obvladovanja med zdravljenjem nastale anemije (glejte poglavje 5.1).
A clinical drug interaction study with digoxin demonstrated that boceprevir is a mild P-gp inhibitor in vivo, increasing digoxin exposure by 19%.
Klinična študija medsebojnega delovanja zdravila z digoksinom je pokazala, da je boceprevir blag zaviralec P-gp in vivo in povečuje izpostavljenost digoksinu za 19 %.
If you have been told by your doctor that you cannot tolerate or digest some sugars (you have an intolerance to some sugars), such as Lapp lactase deficiency, or glucose-galactose malabsorption, talk to your doctor before taking this medicine.
Če vam je zdravnik povedal, da ne prenašate oz. ne prebavljate nekaterih sladkorjev (imate intoleranco za nekatere sladkorje), tj. imate npr. laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze-galaktoze, se z njim posvetujte, preden vzamete to zdravilo.